FHL-4 Activators
FHL-4 Activators encompass a collection of chemical compounds that indirectly promote the functional activity of FHL-4 by modulating various cellular signaling pathways. Forskolin, Isoproterenol, and Dibutyryl-cAMP all function by increasing intracellular levels of cAMP, which in turn activates PKA. This activation can enhance FHL-4 activity by altering the phosphorylation state of associated proteins, particularly within muscle and cardiac tissues where FHL-4 is predominantly expressed. Similarly, PMA activates PKC, which modulates the activity of proteins in close relation to FHL-4 and thus could enhance its regulatory function in cardiac muscle. Calcium ionophores like A23187 and Ionomycin increase intracellular calcium, which is vital for calcium-dependent signaling pathways that can positively influence FHL-4 activity.
Further influencing the functionality of FHL-4, LY294002 and U0126 modulate PI3K and MEK pathways, respectively, thereby indirectly affecting the activity of FHL-4 through changes in the phosphorylation patterns of interacting proteins. SB203580 and KN-93, which inhibit p38 MAPK and CaMKII, may also shift cellular signaling in favor of pathways that augment FHL-4 activity in muscle differentiation and cardiac function. Genistein, by inhibiting tyrosine kinase activity, reduces competitive phosphorylation events that could dampen FHL-4's activity, potentially promoting its role in muscle cells. Lastly, EGCG, with its multi-kinase inhibitory properties, could favor the enhancement of FHL-4's functional interactions by influencing phosphorylation cascades within muscle cells, promoting a cellular environment conducive to FHL-4 activity enhancement.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin indirectly enhances the activity of FHL-4 by elevating intracellular cAMP levels, which can activate protein kinase A (PKA). PKA phosphorylation can influence proteins that interact with FHL-4, thus enhancing its functional activity within the muscle and cardiac tissue where it is expressed. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol acts as a beta-adrenergic agonist, leading to increased cAMP and subsequent activation of PKA. This cascade can potentiate FHL-4 activity by modifying the phosphorylation state of associated proteins in cardiomyocytes. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which can modulate the activity of proteins that associate with FHL-4, enhancing its function in cardiac muscle regulation. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 acts as a calcium ionophore, increasing intracellular calcium concentrations. This can indirectly activate FHL-4 by influencing calcium-dependent signaling pathways and modulating the interaction of FHL-4 with other calcium-binding proteins. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin functions as a calcium ionophore, similar to A23187, increasing intracellular calcium and potentially enhancing FHL-4 activity through calcium-dependent signaling pathways in cardiac cells. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
Dibutyryl-cAMP is a cell-permeable cAMP analog that activates cAMP-dependent pathways, including PKA, which can enhance the functional activity of FHL-4 in muscle tissues. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter downstream signaling pathways, indirectly enhancing the activity of FHL-4 by affecting proteins that modulate its function in myocytes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that may lead to altered expression of proteins within the MAPK pathway, thus indirectly affecting FHL-4 activity in muscle differentiation and cardiac function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could shift signaling towards pathways that enhance FHL-4 activity in skeletal muscle and heart tissue. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII). Inhibition of CaMKII can alter signaling pathways in cardiomyocytes, potentially enhancing FHL-4 activity through the modulation of related proteins. | ||||||